ArticleFrontiers in cardiovascular medicine2022
Long-term outcomes of drug-coated balloons in patients with diffuse coronary lesions.
Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 29 citations in OpenAlex.
- Drug-Coated Balloons Versus Drug-Eluting Stents for Patients With Long De Novo Coronary Artery Lesions: Insights From the REC-CAGEFREE I Trial.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Trial
- Prognostic implications of increased and final quantitative flow ratios in patients treated with drug-coated balloons physiological evaluation after DCB in de novo lesions.BMC cardiovascular disorders · 2024Trial
- Drug-Coated Balloon for Diffuse Coronary Artery Disease.JACC. Asia · 2026Article
- Mid-term outcomes of using drug-coated balloon angioplasty for the treatment of large vesselCardiovascular diagnosis and therapy · 2026Article
- Recent advances in percutaneous coronary intervention for modernizing coronary physiology-guided and device-based strategies for coronary revascularization.Frontiers in medicine · 2026Review
- Impact of drug coated balloon on left anterior descending artery stenosis at proximal to myocardial bridge.Frontiers in cardiovascular medicine · 2026Article
- Temporal trends in the use of drug-coated balloons in Poland - an analysis based on the national registry.Cardiology journal · 2026Article
- Drug-coated balloons and diabetes: a review.Cardiovascular diabetology · 2025Review
- Consensus Statement on Drug-Coated Balloons in Coronary Artery Disease from the Cardiovascular Intervention Association of Thailand.Journal of clinical medicine · 2025Review
- Long-Term Effectiveness of a Stent-Less Strategy With Drug Coated Balloon in Coronary Artery Disease: 3-Year Follow-Up of a Prospective All-Comers Observational Study.Clinical cardiology · 2025Observational
- Drug-Coated Balloons-Based Intervention for Coronary Artery Disease: The Second Report of Asia-Pacific Consensus Group.JACC. Asia · 2025Review
- Drug-Coated Balloons in All-Comer Population-Are We There Yet?Journal of clinical medicine · 2025Review
- Drug-Coated Balloons for Coronary Interventions: A Focused Review.Methodist DeBakey cardiovascular journal · 2025Review
- Drug coated balloons in percutaneous coronary intervention: how can computational modelling help inform evolving clinical practice?Frontiers in medical technology · 2025Review
- Contemporary Use of Drug-Coated Balloons for Coronary Angioplasty: A Comprehensive Review.Journal of clinical medicine · 2024Review
- Drug-Coated Balloon Treatment for De Novo Coronary Lesions: Current Status and Future Perspectives.Korean circulation journal · 2024Review
- Drug-Coated Balloon Angioplasty in Patients Undergoing Complex Percutaneous Coronary Intervention.JACC. Asia · 2024Article
- Chinese expert consensus on the clinical application of drug-coated balloon (2Journal of geriatric cardiology : JGC · 2024Article
- A 2024 scientific update on the clinical performance of drug-coated balloons.AsiaIntervention · 2024Review
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-coated balloons (DCB), alone or in combination with drug-eluting stents (DES), may be used to treat diffuse coronary lesions. We aimed to explore the efficacy and safety of DCB in patients with diffuse coronary lesions. Methods: Consecutive patients with diffuse coronary lesions (lesion length > 25 mm) who underwent DCB and/or DES between January 2015 and December 2019 were included in this prospective, observational, multicenter study. The DCB group included 355 patients (360 lesions), of which 142 patients (143 lesions, 39.7%) received the DCB-only strategy and 213 patients (217 lesions, 60.3%) received the hybrid strategy (DCB combined with DES). The DES group included 672 patients (831 lesions) treated with DES alone. Target lesion revascularization (TLR) during 3-year follow-up was the primary outcome of interest. The secondary outcome was major adverse cardiac events (MACE), defined as a composite of all-cause death, non-fatal myocardial infarction, and target vessel revascularization. Results: The two groups had comparable baseline clinical and lesion characteristics. Lesion length was similar (43.52 ± 16.46 mm vs. 44.87 ± 15.80 mm, Conclusion: Long-term outcomes show that the efficacy and safety of the DCB strategy (DCB alone or combined with DES) are similar to those of DES alone in diffuse coronary lesions. These findings suggest that this strategy is a promising alternative for select patients with diffuse coronary lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.